Transient oscillatory dynamics of interferon beta signaling in macrophages
- Inna Pertsovskaya†1,
- Elena Abad†2, 3,
- Núria Domedel-Puig3,
- Jordi Garcia-Ojalvo2, 3 and
- Pablo Villoslada1Email author
© Pertsovskaya et al.; licensee BioMed Central Ltd. 2013
Received: 8 February 2013
Accepted: 5 July 2013
Published: 9 July 2013
Interferon-beta (IFN-beta) activates the immune response through the type I IFN signaling pathway. IFN-beta is important in the response to pathogen infections and is used as a therapy for Multiple Sclerosis. The mechanisms of self-regulation and control of this pathway allow precise and environment-dependent response of the cells in different conditions. Here we analyzed type I IFN signaling in response to IFN-beta in the macrophage cell line RAW 264.7 by RT-PCR, ELISA and xMAP assays. The experimental results were interpreted by means of a theoretical model of the pathway.
Phosphorylation of the STAT1 protein (pSTAT1) and mRNA levels of the pSTAT1 inhibitor SOCS1 displayed an attenuated oscillatory behavior after IFN-beta activation. In turn, mRNA levels of the interferon regulatory factor IRF1 grew rapidly in the first 50–90 minutes after stimulation until a maximum value, and started to decrease slowly around 200–250 min. The analysis of our kinetic model identified a significant role of the negative feedback from SOCS1 in driving the observed damped oscillatory dynamics, and of the positive feedback from IRF1 in increasing STAT1 basal levels. Our study shows that the system works as a biological damped relaxation oscillator based on a phosphorylation-dephosphorylation network centered on STAT1. Moreover, a bifurcation analysis identified translocation of pSTAT1 dimers to the nucleus as a critical step for regulating the dynamics of type I IFN pathway in the first steps, which may be important in defining the response to IFN-beta therapy.
The immunomodulatory effect of IFN-beta signaling in macrophages takes the form of transient oscillatory dynamics of the JAK-STAT pathway, whose specific relaxation properties determine the lifetime of the cellular response to the cytokine.
KeywordsType I interferon pathway Interferon-beta Ordinary differential equation Oscillations Multiple sclerosis Immunotherapy
Type I interferons, such as interferon alfa and beta, are cytokines that represent a first-line endogenous defense mechanism in response to viruses and bacterial infections, are secreted by many cell types (e.g. lymphocytes, macrophages and endothelial cells) and they are used as a therapy in Multiple Sclerosis (MS).
The target genes of the IFN-beta pathway can be divided into three categories according to the type of activating transcription factor: 1) the ISGF3 complex activates genes containing an ISRE binding site in their promoter (e.g. ISG15, Mx1, OAS1, IRF7). 2) The GAF complex activates genes containing a GAS binding site in their promoter, such as SOCS1 and IRF1 [3, 4]. 3) A third class of STAT protein complexes activates other canonical pathways that exhibit crosstalk with the JAK/STAT pathway (such as PI3K, NFkB, MAPK) . Recently it was shown that different immune cell subtypes respond differently to IFN-beta induction through activation of these different types of genes .
Different proteins regulate STAT1 phosphorylation. Importantly, a negative feedback loop upon STAT1 activation coexists with a positive feedback mechanism. First, the phosphorylation of STAT1 is inhibited by its inhibitor SOCS1 . The SOCS1 protein then inhibits STAT1 phosphorylation at the kinase level. Besides this negative loop based on SOCS1, STAT1 is a subject to positive regulation via the TF IRF1, whose transcription is induced by activated STAT1. IRF1 promotes the expression of the STAT1 gene at the transcriptional level. Given the existence of these multiple feedback loops, a mathematical modeling of the system would help provide an understanding of the response to type I IFN-beta.
Here we analyzed the type-I IFN-beta signaling pathway in macrophages, showing that the response of this pathway to IFN-beta stimulation takes the form of transient oscillations in STAT1 phosphorylation. We characterized and identified the critical elements governing the transient dynamics of IFN activation, and examined the influence of this dynamical regime in the response to IFN-beta.
Dynamical models of IFN induction of the JAK/STAT signaling pathway based on nonlinear ordinary differential equations, have been previously used to study the effect of IFN pre-treatment on the response of the immune system to virus infection [8, 9] and the robustness of the pathway to noise and parameter fluctuations , among other problems. Systems biology approaches have also been applied to this pathway in order to examine its role in certain pathological mechanisms underlying the behavior of cancer cells , and its interaction with other key signaling pathways [8, 12]. Here we combine our theoretical model with experimental observations. Our results show that a combination of positive and negative feedback loops, together with the eventual degradation of the IFN signal in the medium, leads to a transient oscillatory response in several components of the pathway. This behavior is consistent with previous numerical results found in pure modeling studies , and goes beyond previous observations that indicate a simpler transient response [10, 14, 15]. We interpret the transient oscillatory response of the pathway in terms of the potential effectiveness of IFN-beta treatment in MS patients.
IFN-beta induces a transient oscillatory activation of the STAT1 pathway
It is well known that microbial and viral infections induce endogenous IFN-beta release by macrophages as part of the immune cell system response. We could observe IFN-beta production accompanied with significant increases in levels of phosphorylated STAT1 in the murine macrophage-like cell line RAW 264.7 stimulated with lipopolysaccharide (LPS) endotoxin and also, with viral fragments (poly(I:C)) (data not shown). In this study we focused on STAT1 signaling by IFN-beta stimulation in macrophages by challenging the RAW cell line with increasing concentrations of mouse IFN-beta.
To analyze the expression of regulatory genes of the type I IFN pathway, we measured the levels of two downstream STAT1 genes, SOCS1 (responsible of the negative feedback) and IRF1 (mediator of the positive feedback). We observed an oscillatory behavior of SOCS1 mRNA during the first 360 minutes after stimulation, with clear peaks at around 90 min and 250 min, before returning to baseline levels (Figure 3C). On the other hand, IRF1 shows different dynamics, with its concentration raising quickly between 30 and 120 min, then reaching a plateau and decreasing more slowly after 250 min (Figure 3B). We also quantified the expression levels of other downstream effector IFN-induced genes, such as MX1 and OAS1b, but did not identify any activation of their transcription in the RAW 264.7 cell line after IFN-beta stimulation (data not shown). These observations are in agreement with a differential signal transduction mechanism in macrophages when compared to canonical JAK-STAT pathway in lymphocytes [4, 18]. Our observations show that in the RAW 264.7 cell line the main activated genes were the ones controlled by the STAT1-STAT1 homodimer (IRF1 and SOCS1) and containing GAS elements in their promoter region. These genes are mainly responsible for the antimicrobial activity of the cells .
Modeling the oscillatory signaling of type I IFN pathway
Parameter values obtained from the literature
Parameters for type I IFN ODE model
Translation rate for STAT1
Receptor production rate
Basal STAT1 RNA
Transcription rate for STAT1
Transcription rate for SOCS1
Transcription rate for IRF1
Translation rate for IRF1
1.0 · 101
Translation rate for SOCS1
1.0 · 102
Phosphorylation STAT1 rate
1.3 · 103
Dephosphorylation STAT1 rate
Import to the nucleus rate (pSTAT1)
Export from the nucleus rate (STAT1)
STAT1 phosphorylation activation (Hill’s constant; half maximal activation)
Dissociation constant for the enzyme-inhibitor by SOCS1 (Hill’s constant; half maximal activation)
SOCS1 transcription activation by nuclear pSTAT1 (Hill’s constant; half maximal activation)
IRF1 transcriptional activation by pSTAT1
STAT1 transcriptional activation by IRF1
1.3 · 105
Cooperativity of SOCS1 protein over STAT1 dimers
Cooperativity of STAT1 on SOCS1 gene promoter
Cooperativity of STAT1 on IRF1 gene promoter
Cooperativity of IRF1 on STAT1 gene promoter
Receptor internalization/degradation rate
SOCS1 RNA degradation rate
SOCS1 protein degradation rate
IRF1 RNA degradation rate
IRF1 protein degradation rate
STAT1 RNA degradation rate
STAT1 protein degradation rate
Initial conditions for type I IFN model simulations
1.0 · 105 molecules
IFN activation receptor
Phosphorylated nuclear STAT1
Phosphorylated cytoplasmic STAT1
The right panels in Figures 2 and 3 show simulation results corresponding to the experimental observations presented in the left panels. For comparative purposes, both the experimental and model variables were shown in relative concentrations dividing by their maximum value along the time series. We also performed a sensitivity analysis by simulating changes of ±20% for every model parameter, leading to deviations from the basal curve falling within the shaded areas shown in Figures 2 and 3.
The model simulations reproduce the main features observed experimentally, such as the first and very fast peak of phosphorylated STAT1 shortly after IFN-beta stimulation, and the second peak of smaller amplitude at around 200 min (Figure 2D). The concentration of total STAT1 protein is almost constant during the first 200 min, after which the protein level increases slowly (Figure 2E), following the increased expression level of STAT1 mRNA, which mRNA grows slowly starting at around 50 min after stimulation (Figure 3D). In turn, SOCS1 mRNA levels increase from the beginning, showing a first peak at around 90 min and a second smaller peak following the second peak of phosphorylated STAT1 at around 250 min (Figure 3F), in agreement with the experiments. Again similarly to the experiments, IRF1 mRNA levels show a bell-shaped time course (Figure 3E), with an increase resembling that of SOCS1 mRNA levels (Figure 3F) and remaining high from around 90 min to 250 min, when IRF1 mRNA levels decrease to half their maximum value at around 350 min.
Bifurcation analysis of the STAT1 pathway model identifies translocation to the nucleus as a critical step
The temporal evolution of the phosphorylation of STAT1 can be crucial for understanding the response to IFN-beta therapy, and may provide an explanation of the lack of response to this therapy in some cases . In particular, transient oscillatory dynamics could provide a way for the STAT1 pathway to increase the duration of its response to IFN-beta in a physiological manner (i.e. without a period of sustained constant activation as in Figure 5B). In order to establish the conditions under which this transient dynamics exists, we analyzed the behavior of the system for combinations of two-parameter pairs, distinguishing between the parameter values for which pSTAT dynamics is overdamped (and thus non-oscillatory) and those for which the oscillations are underdamped (which corresponds to the experimental situation reported above). We focused on the phosphorylation and dephosphorylation rates (b ph and b deph ) and export and import rates (b exp and b imp ). These parameters represent crucial steps to regulate the nuclear availability of transcription factors such as pSTAT dimers, and thus also the expression of downstream genes.
We also tested the influence of the import rate of pSTAT1 molecules into the nucleus, and of the export rate of STAT1 from the nucleus into the cytosol. By tuning both parameters (b exp and b imp ) simultaneously, we observed again that the transient oscillatory regime is prevalent in this system (Figure 7C). We found that the oscillatory regime is associated with high nuclear import rates in combination with high export rates. For high export rates but low import rates, the pathway exhibits an overdamped (non-oscillatory) response, showing a sustained plateau in the transient level of pSTAT1 (discontinuous blue line in Figure 7D). Conversely, for high import rates and low export rates the response is also overdamped, but with a faster decay (continuous blue line in Figure 7D).
The aim of this work was to characterize the dynamics of the key components of the type I IFN-beta signaling pathway in macrophage RAW 264.7 cells. This system robustly translates extracellular chemical signals through cell membrane receptors, leading to phosphorylation of the STAT transcription factors, which induce gene expression of multiple targets. JAK/STAT signaling directly regulates the immune system response under viral or bacterial infection, and is also important in autoimmune diseases and cancer treatments. The IFN signaling network affects different complex pathways, involving processes such as differentiation, proliferation, survival and cell death. Importantly, it is a canonical pathway involved in first-line treatments of multiple sclerosis as a main target of the IFN system  but, also, affects different complex pathways, involving processes such as differentiation, proliferation or survival and cell death [26, 27].
In this paper, we used a combination of experimental approaches in order to obtain a quantitative picture of the response of the JAK/STAT signaling pathway to IFN-beta stimulation, and to identify the most relevant aspects of its dynamics to be modeled with kinetic equations. Experiments uncovered several important features of JAK/STAT signaling dynamics during the first eight hours after treatment with IFN-beta. For example, our results showed the transient oscillatory nature of STAT1 activation (pSTAT1), with a fast increase in cytosol concentration early after stimulation (within the first hour), followed by a secondary concentration peak at around 200 min. A key STAT1 transcription target such as SOCS1 also showed two peaks of expression (correlated in time to the pSTAT peaks) at around 90 min and 250 min after stimulation, whereas another important target, namely IRF1, exhibited a more bell-shaped plateau signal, respectively (Figures 2 and 3). Our model simulations also exhibit a transient oscillatory behavior in pSTAT1 concentration, and reveal that the oscillations require the presence of a negative feedback loop on STAT1, mediated by its phosphorylation inhibitor SOCS1. Previous mathematical models of the type I and type II IFN pathways have suggested the possibility that STAT1 pathway has an oscillatory behavior [9, 13] and indicated the importance of the SOCS1 negative feedback [10, 14, 28, 29]. Another factor that has been proposed to be important in defining the response to IFN is the basal level of receptors of the JAK/STAT pathway . In our model this aspect was also taken into account, showing clear effects on the dynamics of the pathway response (Figure 6). Going beyond previous models, our theoretical results show that the physiological regime of the pathway’s response to IFN-beta takes the form of damped oscillations that can be identified by means of a stability analysis of the model’s steady state solution. This analysis shows that processes such as the phosphorylation and dephosphorylation of pSTAT1, and the transport of STAT1 between the nuclear and cytosol compartments, can make the pathway switch between underdamped and overdamped oscillatory regimes .
Implications of the type I IFN signaling dynamics in autoimmune diseases
IFN-beta is the most common treatment for MS , exerting a pleiotropic immunomodulatory activity not well understood . IFN-beta treatment decreases activation, proliferation, cytokine release, and migratory properties of activated T cells, diminishing their ability to enter and damage the brain tissue. In spite of these properties, up to 40% of patients do not respond to IFN-beta therapy, which represents a significant health problem . Previous genomic studies have identified certain genes belonging to the IFN pathway that are associated with a lack of response to IFN-beta, suggesting that the genetic background of certain individuals may modulate this pathway, and consequently the response to therapy, by specific transcriptional profiles . For example, it was recently shown that the response to IFN-beta differs between immune cells, and an analysis of non-responders to IFN-beta therapy indicates an impairment of the type I IFN pathway in the monocytes of those patients [6, 34].
Our study indicates the importance of identifying the temporal dynamics of the concentration of certain key components of the JAK-STAT pathway, such as the phosphorylated form of the STAT1 protein, and of the expression of interferon-stimulated transcription genes like SOCS1 and IRF1, within the first 8 hours of IFN-beta administration. Cataloguing these dynamics could provide us with early molecular biomarkers that allow us to distinguish the lack of response to IFN-beta therapy of certain MS patients.
Materials and reagents
Cells were obtained from ATCC library, mouse recombinant IFN-beta was purchased from Cell sciences, lipopolysaccharide from Escherichia coli and poly(I:C) salt was purchased from Sigma-Albrich, lipofectamine 2000, Hiperfect transfection agent were purchased from QIAGEN, Taqman PCR master mix, VIC-dye GAPDH endogenous control, IRF1, SOCS1, STAT1, STAT2, MX1, OAS1a pre-designed FAM-dye assays were purchased from Applied Biosystems, total STAT1 and STAT1(pTyr701) antibodies and beads, cell detection kit for xMAp assays were purchased from Merck Millipore (Billerica). Alexa Flour 647 STAT1 (pTyr701) and PE STAT1 N-terminal anti-Mouse antibodies and all buffers for cytometry were purchased from BD biosciences. APC-labelled IFNAR1 antibody was purchased from Biolegend.
Cell culture and stimulation
Mouse leukemic monocyte macrophage cell line RAW 264.7 cell line was purchased from ATCC and maintained in DMEM medium complemented with 10% fetal bovine serum and 1% antibiotics at 37°C and 5% CO2. The cells were passed every 2–3 days and maintained in 20-80% surface coverage. One day before the stimulation the cells were seeded in 12 well plates in concentration 1 × 106 cells/well. The cells were stimulated with 1000 units of recombinant mouse IFN-beta, 15 μg of LPS for different times or 15 μg of poly (I:C) solution. At the end of stimulation supernatants or cells were collected for further analysis. The same amount of PBS was added at the corresponding time-points to the control samples.
Cell lysates were prepared with QiaShredder columns and total RNA was isolated using standard Qiagen Rnaesy Mini kit protocol. Equal amount of total RNA was added to each reverse transcription reaction tube (High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems and cDNA was used for a second step of RT-PCR. Results were analyzed using relative 2CTT method normalized to a GAPDH endogenous control (VIC-dye primer-limited control from Applied Biosystems) as described before . All the qRT-PCR experiments were performed in triplicates and repeated three times independently.
Western blot and quantification
Western blot (WB) was performed using polyclonal rabbit anti-mouse pSTAT1 and STAT1 N-terminal antibodies (Abcam) using standard WB protocol. Western blot results were quantified using ImageJ software (http://rsb.info.nih.gov/ij/index.html) using the method of Luke Miller (http://www.lukemiller.org/journal/2007/08/quantifying-western-blots-without.html)
ELISA and xMAP multiplexing assays
IFN-beta in culture supernatants and SOCS1 protein concentration in cell lysates were measured by standard sandwich ELISA with anti-mouse SOCS1 antibodies (Abcam). IRF1 protein concentration in cell lysates was measured by in-cell ELISA using the kit (Thermo Scientific) STAT1 total protein and phosphorylated state (Tyr701) concentrations (nuclear and cytoplasmic together) were measured using xMAP assays and read in Luminex 201 platform using standard vacuum separation protocol (Millipore). xMAP experiments were repeated twice.
Cells for flow cytometry were stimulated with 1,000 μn/ml of IFN-beta as stated before and fixed immediately after stimulation. IFNAR1 receptor on the surface of the RAW 264.7 cells was marked using APC-labelled anti-IFNAR antibody. The mean fluorescent intensity was calculated using FlowJo software. For STAT1 staining cells were fixed immediately after stimulation in order to preserve phosphorylation and then permeabilized using Perm III buffer (BD biosciences). Samples were stained simultaneously with anti-STAT1 (pTyr701) and anti-STAT1 total (N-terminus) antibodies. The mean fluorescent intensity, the percent of staining-positive cells, the medians and the standard deviation were calculated using FlowJo software and the raw single-cell data were extracted to plot the histograms and further analysis.
The model and simulations were run in MATLAB using the ODE15s solver (Matlab codes are provided in the Additional files 1, 2 and 3). The stability analysis of the dynamical system was performed with custom-made Matlab codes.
Availability of supporting data
The model is available as a matlab script in the supporting materials. The raw experimental data are available from the authors upon request.
ordinary differential equations
Signal Transducers and Activators of Transcription 1
Suppressor of cytokine signaling 1
Interferon regulatory factor 1
Interferon-sensitive response element
Interferon-Gamma Activated Sequence
IFN-stimulated regulatory factor 3
C): Polyinosinic:polycytidylic acid
quantitative reverse transcription polymerase chain reaction
Glyceraldehyde 3-phosphate dehydrogenase
Enzyme-Linked Immunosorbent Assay
- OAS1a - 2'-5':
oligoadenylate synthetase 1 gene
Interferon-induced GTP-binding protein gene.
This work was supported by the EU 6FP ComplexDis project (NEST-043241), the EU 7FP – Marie Curie initial training network UEPHA*MS (ITN-212877) and Fundacion Cellex to PV; by the Spanish network of excellence in MS of the Instituto de Salud Carlos III, Spain to PV and JGO (RD07/0060) and by the Fundación Mutua Madrileña to PV and JGO; by a grant of the Ministerio de Economia y Competitividad and Fondo Europeo de Desarrollo Regional (Spain, project FIS2012-37655) and by the ICREA Academia program to JGO.
- Rawlings JS, Rosler KM, Harrison DA: The JAK/STAT signaling pathway. J Cell Sci. 2004, 117 (Pt 8): 1281-1283.PubMedView ArticleGoogle Scholar
- Imada K, Leonard WJ: The Jak-STAT pathway. Mol Immunol. 2000, 37 (1–2): 1-11.PubMedView ArticleGoogle Scholar
- Qin H, Wilson CA, Lee SJ, Benveniste EN: IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. Faseb J. 2006, 20 (7): 985-987. 10.1096/fj.05-5493fje.PubMedView ArticleGoogle Scholar
- van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, Stark GR: Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol. 2010, 185 (10): 5888-5899. 10.4049/jimmunol.0902314.PubMedPubMed CentralView ArticleGoogle Scholar
- Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I: Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011, 17 (9): 2619-2627. 10.1158/1078-0432.CCR-10-1114.PubMedView ArticleGoogle Scholar
- Oliver-Martos B, Orpez T, Pinto-Medel MJ, Mayorga C, Garcia-Leon JA, Maldonado-Sanchez R, Suardiaz M, Guerrero M, Luque G, Leyva L, Fernandez O: Gene expression in IFNss signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients. J Neuroimmunol. 2011, 230 (1–2): 153-159.PubMedView ArticleGoogle Scholar
- Starr R, Hilton DJ: SOCS: suppressors of cytokine signalling. Int J Biochem Cell Biol. 1998, 30 (10): 1081-1085. 10.1016/S1357-2725(98)00067-3.PubMedView ArticleGoogle Scholar
- Raza S, Robertson KA, Lacaze PA, Page D, Enright AJ, Ghazal P, Freeman TC: A logic-based diagram of signalling pathways central to macrophage activation. BMC Syst Biol. 2008, 2: 36-10.1186/1752-0509-2-36.PubMedPubMed CentralView ArticleGoogle Scholar
- Qiao L, Phipps-Yonas H, Hartmann B, Moran TM, Sealfon SC, Hayot F: Immune response modeling of interferon beta-pretreated influenza virus-infected human dendritic cells. Biophys J. 2010, 98 (4): 505-514. 10.1016/j.bpj.2009.10.049.PubMedPubMed CentralView ArticleGoogle Scholar
- Smieja J, Jamaluddin M, Brasier AR, Kimmel M: Model-based analysis of interferon-beta induced signaling pathway. Bioinformatics. 2008, 24 (20): 2363-2369. 10.1093/bioinformatics/btn400.PubMedPubMed CentralView ArticleGoogle Scholar
- Vera J, Rateitschak K, Lange F, Kossow C, Wolkenhauer O, Jaster R: Systems biology of JAK-STAT signalling in human malignancies. Prog Biophys Mol Biol. 2011, 106 (2): 426-434. 10.1016/j.pbiomolbio.2011.06.013.PubMedView ArticleGoogle Scholar
- Swameye I, Muller TG, Timmer J, Sandra O, Klingmuller U: Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc Natl Acad Sci USA. 2003, 100 (3): 1028-1033. 10.1073/pnas.0237333100.PubMedPubMed CentralView ArticleGoogle Scholar
- Soebiyanto RP, Sreenath SN, Qu CK, Loparo KA, Bunting KD: Complex systems biology approach to understanding coordination of JAK-STAT signaling. Biosystems. 2007, 90 (3): 830-842. 10.1016/j.biosystems.2007.05.005.PubMedPubMed CentralView ArticleGoogle Scholar
- Yamada S, Shiono S, Joo A, Yoshimura A: Control mechanism of JAK/STAT signal transduction pathway. FEBS Lett. 2003, 534 (1–3): 190-196.PubMedView ArticleGoogle Scholar
- Shudo E, Yang J, Yoshimura A, Iwasa Y: Robustness of the signal transduction system of the mammalian JAK/STAT pathway and dimerization steps. J Theor Biol. 2007, 246 (1): 1-9. 10.1016/j.jtbi.2006.11.016.PubMedView ArticleGoogle Scholar
- Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A: A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997, 387 (6636): 921-924. 10.1038/43213.PubMedView ArticleGoogle Scholar
- Nguyen H, Lin R, Hiscott J: Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. Oncogene. 1997, 15 (12): 1425-1435. 10.1038/sj.onc.1201318.PubMedView ArticleGoogle Scholar
- Lucas DM, Lokuta MA, McDowell MA, Doan JE, Paulnock DM: Analysis of the IFN-gamma-signaling pathway in macrophages at different stages of maturation. J Immunol. 1998, 160 (9): 4337-4342.PubMedGoogle Scholar
- Sadler AJ, Williams BR: Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008, 8 (7): 559-568. 10.1038/nri2314.PubMedPubMed CentralView ArticleGoogle Scholar
- Piganis RA, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, Hertzog PJ: Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem. 2011, 286 (39): 33811-33818. 10.1074/jbc.M111.270207.PubMedPubMed CentralView ArticleGoogle Scholar
- Toni T, Stumpf MP: Parameter inference and model selection in signaling pathway models. Methods Mol Biol. 2010, 673: 283-295. 10.1007/978-1-60761-842-3_18.PubMedView ArticleGoogle Scholar
- Garcia-Ojalvo J: Physical approaches to the dynamics of genetic circuits: a tutorial. Contemporary Physics. 2011, 52 (5): 439-464. 10.1080/00107514.2011.588432.View ArticleGoogle Scholar
- Marijanovic Z, Ragimbeau J, van der Heyden J, Uze G, Pellegrini S: Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J. 2007, 407 (1): 141-151. 10.1042/BJ20070605.PubMedPubMed CentralView ArticleGoogle Scholar
- Villoslada P, Oksenberg JR, Rio J, Montalban X: Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2004, 62 (9): 1653-author reply 1653PubMedView ArticleGoogle Scholar
- Javed A, Reder AT: Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther. 2006, 110 (1): 35-56. 10.1016/j.pharmthera.2005.08.011.PubMedView ArticleGoogle Scholar
- Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev. 2001, 14 (4): 778-809. 10.1128/CMR.14.4.778-809.2001. table of contentsPubMedPubMed CentralView ArticleGoogle Scholar
- Lohoff M, Mak TW: Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol. 2005, 5 (2): 125-135. 10.1038/nri1552.PubMedView ArticleGoogle Scholar
- Rateitschak K, Karger A, Fitzner B, Lange F, Wolkenhauer O, Jaster R: Mathematical modelling of interferon-gamma signalling in pancreatic stellate cells reflects and predicts the dynamics of STAT1 pathway activity. Cell Signal. 2010, 22 (1): 97-105. 10.1016/j.cellsig.2009.09.019.PubMedView ArticleGoogle Scholar
- Ramgolam VS, Markovic-Plese S: Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis. J Signal Transduct. 2011, 2011: 635721-PubMedPubMed CentralView ArticleGoogle Scholar
- Zurney J, Howard KE, Sherry B: Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol. 2007, 81 (24): 13668-13680. 10.1128/JVI.01172-07.PubMedPubMed CentralView ArticleGoogle Scholar
- Takaoka A, Yanai H: Interferon signalling network in innate defence. Cell Microbiol. 2006, 8 (6): 907-922. 10.1111/j.1462-5822.2006.00716.x.PubMedView ArticleGoogle Scholar
- Marta M, Giovannoni G: Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. CNS Neurol Disord Drug Targets. 2012, 11 (5): 610-623. 10.2174/187152712801661301.PubMedView ArticleGoogle Scholar
- Rio J, Comabella M, Montalban X: Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009, 5 (10): 553-560. 10.1038/nrneurol.2009.139.PubMedView ArticleGoogle Scholar
- Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, Julia E, Fernandez M, Nonell L, Camina-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R: A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009, 132 (Pt 12): 3353-3365.PubMedView ArticleGoogle Scholar
- Palacios R, Goni J, Martinez-Forero I, Iranzo J, Sepulcre J, Melero I, Villoslada P: A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS ONE. 2007, 2 (11): e1222-10.1371/journal.pone.0001222.PubMedPubMed CentralView ArticleGoogle Scholar
- Haspel RL, Salditt-Georgieff M, Darnell JE: The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. Embo J. 1996, 15 (22): 6262-6268.PubMedPubMed CentralGoogle Scholar
- Gao C, Guo H, Mi Z, Grusby MJ, Kuo PC: Osteopontin induces ubiquitin-dependent degradation of STAT1 in RAW264.7 murine macrophages. J Immunol. 2007, 178 (3): 1870-1881.PubMedView ArticleGoogle Scholar
- Qin H, Niyongere SA, Lee SJ, Baker BJ, Benveniste EN: Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J Immunol. 2008, 181 (5): 3167-3176.PubMedPubMed CentralView ArticleGoogle Scholar
- Wong LH, Sim H, Chatterjee-Kishore M, Hatzinisiriou I, Devenish RJ, Stark G, Ralph SJ: Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1. J Biol Chem. 2002, 277 (22): 19408-19417. 10.1074/jbc.M111302200.PubMedView ArticleGoogle Scholar
- Sharova LV, Sharov AA, Nedorezov T, Piao Y, Shaik N, Ko MS: Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells. DNA Res. 2009, 16 (1): 45-58. 10.1093/dnares/dsn030.PubMedPubMed CentralView ArticleGoogle Scholar
- Wenta N, Strauss H, Meyer S, Vinkemeier U: Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci USA. 2008, 105 (27): 9238-9243. 10.1073/pnas.0802130105.PubMedPubMed CentralView ArticleGoogle Scholar
- Killion JJ, Fishbeck R, Bar-Eli M, Chernajovsky Y: Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors. Cytokine. 1994, 6 (4): 443-449. 10.1016/1043-4666(94)90069-8.PubMedView ArticleGoogle Scholar
- Andrejeva J, Young DF, Goodbourn S, Randall RE: Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons. J Virol. 2002, 76 (5): 2159-2167. 10.1128/jvi.76.5.2159-2167.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Nakagawa K, Yokosawa H: Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. Eur J Biochem. 2000, 267 (6): 1680-1686.PubMedGoogle Scholar
- Fujita T, Reis LF, Watanabe N, Kimura Y, Taniguchi T, Vilcek J: Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. Proc Natl Acad Sci USA. 1989, 86 (24): 9936-9940. 10.1073/pnas.86.24.9936.PubMedPubMed CentralView ArticleGoogle Scholar